Flourish Fete

Trent and Molly Cameron

Suzanne Donaghey and Emilie Ulicsni

Leah and Greg Austin Dr. Katie Erdlitz, Dr. Katrina Skinner and Natalie Clarke Natalie Wynn and Crystal Bailey

Madeline Crawley and Allie Ward

Carol and John Richter

Photos by Ruili Cai Supporters of Flourish Teen Center for Girls joined together at Eastern Shore Art Center to enjoy tasty hors d’oeuvres from The Roaming Oyster, cocktails from Tap and Pour, live music, and a silent auction featuring beautiful art along with other items. Flourish, located in Daphne, provides a community space for teen girls to grow in a healthy way.

Lauren Hoffman and Courtney Gordon Alle and Suzanne Johnson

SOCIAL

Caryn Buchanan and Meridith South

Sierra Daughtery, Monica Nash, Suzanne Donaghey and Emilie Ulicsni

ERIN MOODY, CORTNEY MORRIS, KRISTEN NIBLETT AND LAWREN REAVES

Janie Widemire, Darin Wynn, Natalie Wynn, Stephanie Robinson and Ryan Robinson

Canterbury Park is a gated residential subdivision located in the heart of Spring Hill catering to those who want to reside in a highend community and minimize the worries of everyday property maintenance. Twelve private lots make up the exceptional development where each home plan has been exclusively designed by McCown Design and landscaping design by WAS Design

Cole Lucky and Sydney Wasdin Brittney Lundy and Stephanie Tunstall Casey Williams and Rose Ann Haven

Dena Pittman, Cindy Zebryk, Amy Cuny and Jennifer Neto Natalie Clarke, Kalla Bufkin, Maggie Norton, Marci Malec, Rebecca Roberts and Amy Kranz

Kelly Ross, Meredith Ivy and Denise King John Richter, Darin Wynn, Natalie Wynn, Carol Richter, Leah Austin and Greg Austin

LOTS AVAILABLE

LUXURY LIVING IN SPRING HILL

www.canterburyparkmobile.com www.llbb.com | 251.342.3200 MELISSA MORRISSETTE | mmorrissette@llbb.com | 251.709.4736 FRANCES WILLIAMS | fwilliams@llbb.com | 251.463.5168

Mitchell Cancer Institute Mitchell Cancer Institute is Transforming is Transforming Breast Cancer Care. Breast Cancer Care.

Donna Lynn Dyess, MD Breast Surgeon Principal Investigator, Lumicell Pivotal Breast Cancer Trial Donna Lynn Dyess, MD Breast Surgeon Principal Investigator, Lumicell Pivotal Breast Cancer Trial

When it comes to breast cancer, the USA Health Mitchell Cancer Institute (MCI) is the region’s only academic cancer research center providing patients along the upper Gulf Coast with unparalleled access to cutting-edge technology. As a breast surgeon and principal investigator (PI) for the recently completed Lumicell Feasibility and Pivotal Breast Cancer Trial, Donna Lynn Dyess, M.D., championed a new investigational approach* in surgical oncology that has the potential to transform breast cancer care in our region. The MCI is one of only 14 facilities in the United States and the only site in Alabama who participated in the trial, identifying a number of qualifying breast cancer patients. Through the MCI’s commitment to clinical trials and research, breast cancer patients are provided the opportunity to receive new and exploratory surgical techniques that would otherwise not be available to them. The MCI’s team of fellowship-trained surgeons and specialists work together to offer the most comprehensive breast cancer care to patients in our community. Dr. Dyess is passionate about providing breast cancer patients the opportunity to be a part of progressive research and leading-edge medicine at the MCI.

When it comes to breast cancer, the USA Health Mitchell Cancer Institute (MCI) is the region’s only academic cancer research center providing patients along the upper Gulf Coast with unparalleled access to cutting-edge technology. As a breast surgeon and principal investigator (PI) “To optimize each patient’s chance of beating cancer, it takes evaluating new approaches in surgical oncology. The Lumicell trial provided the opportunity to evaluate and make optimizations in real time with the goal of giving the highest quality breast cancer care,” says Dr. Dyess. for the recently completed Lumicell Feasibility and Pivotal Breast Cancer Trial, Donna Lynn Dyess, M.D., championed a new investigational approach* in surgical oncology that has the potential to transform breast cancer care in our region. The MCI is one of only 14 facilities in the United States and the only site in Alabama who participated in the trial, identifying a number of qualifying breast cancer patients. Breast-conserving surgery is a critical first step of treatment. The goal is to remove all cancerous cells, leaving behind only healthy tissue. In as many as 20-40% of breast cancer cases, cancer cells are found at the margins of the removed tissue, typically requiring patients to undergo a second surgery to extract remaining cancer. Lumicell’s image-guided technology aimed to change the way breast cancer is treated Through the MCI’s commitment to clinical trials and research, breast cancer patients are provided the opportunity to receive new and exploratory surgical techniques that would otherwise not be available to by empowering surgeons to identify and remove all cancer cells during the initial surgery, with the goals of reducing the chances of repeat surgeries, improving surgical outcomes and reducing health care costs. them. The MCI’s team of fellowship-trained surgeons and specialists work together to offer the most comprehensive breast cancer care to patients in our community. Dr. Dyess is passionate about providing The MCI’s team combines clinical care, education and research to push the envelope and deliver innovative solutions, resulting in improved cancer outcomes. breast cancer patients the opportunity to be a part of progressive research and leading-edge medicine at the MCI. “To optimize each patient’s chance of beating cancer, it takes evaluating new approaches in surgical oncology. The Lumicell trial provided the opportunity to evaluate and make optimizations in real time with the goal of giving the highest quality breast cancer care,” says Dr. Dyess. Breast-conserving surgery is a critical first step of treatment. The goal is to remove all cancerous cells, leaving behind only healthy tissue. In as many as 20-40% of breast cancer cases, cancer cells are found at the margins of the removed tissue, typically requiring patients to undergo a second surgery to extract remaining cancer. Lumicell’s image-guided technology aimed to change the way breast cancer is treated by empowering surgeons to identify and remove all cancer cells during the initial surgery, with the goals of reducing the chances of repeat surgeries, improving surgical outcomes and reducing health care costs. The MCI’s team combines clinical care, education and research to push the envelope and deliver innovative solutions, resulting in improved cancer outcomes. To learn more about the MCI’s leading-edge research and multidisciplinary approach, visit usamci.com or call 251.660.5763. To learn more about the MCI’s leading-edge research and multidisciplinary approach, visit usamci.com or call 251.660.5763.